Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: VI-0521 Clear all
Completed Phase 4 Interventional Results available

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

NCT03922945
View directory record Official record
Conditions
Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions
VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
Drug · Behavioral
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

NCT00768209
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Phentermine and Topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

NCT00554216
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, Placebo matched phentermine/topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

NCT00563368
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

NCT00553787
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • Ridgefield, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

NCT00600067
View directory record Official record
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

NCT00745251
View directory record Official record
Conditions
Sleep Apnea
Interventions
VI-0521, placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

NCT00737633
View directory record Official record
Conditions
Diabetes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

NCT00821496
View directory record Official record
Conditions
Healthy
Interventions
ethinyl estradiol, norethindrone, VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 64 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

NCT00486291
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
VI-0521, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

NCT00839891
View directory record Official record
Conditions
Torsades de Pointes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

NCT00806260
View directory record Official record
Conditions
Overweight, Obesity
Interventions
VI-0521, Placebo, Alcohol, alcohol placebo
Drug · Other
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

NCT05215418
View directory record Official record
Conditions
Blood Pressure
Interventions
VI-0521, Phentermine, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Anniston, Alabama • Mobile, Alabama • Lincoln, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 18, 2026, 4:58 AM EDT